Akagera Medicines, Inc

Akagera Medicines is a private Delaware-registered company that develops novel and patented liposomal formulations of antibacterial drugs to treat tuberculosis and other infectious diseases. The company was founded in 2018 in Kigali, Rwanda. It is well-funded, majority-owned by the people of Rwanda, and has laboratories in Boston and San Francisco. Akagera registered a 100%-owned subsidiary in Kigali in 2022 to do manufacturing and clinical trials in the future. Liposomal therapeutics represent a well-validated platform of drug delivery systems that are used for the treatment of a wide range of diseases. They include systemic fungal infections, mycobacterium avium, and cancers. They are utilized to alter the biodistribution of the encapsulated drug and the exposure profile for the drug, and impact both the efficacy and the toxicity (the therapeutic index) of the active drug. The company has developed a therapeutic for MRSA, and vaccine candidates for Tuberculosis, Lassa Fever, HIV, RSV, and Influenza. The vaccine candidates are being developed in close partnership with THE GATES FOUNDATION, the National Institute of Health (NIH) – Vaccine Research Council (VRC), the Coalition for Epidemic Preparedness Innovations (CEPI), and a public pharmaceutical company.